UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2023
Commission File Number: 001-41661
JIN MEDICAL INTERNATIONAL LTD.
No. 33 Lingxiang Road, Wujin District
Changzhou City, Jiangsu Province
People’s Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
On April 6, 2023, Prime Number Capital, LLC, as the representative of the underwriters of the initial public offering (“IPO”) of Jin Medical International Ltd. (the “Company”), partially exercised the over-allotment option to purchase an additional 47,355 ordinary shares at the IPO price of $8.00 per share. As a result, the Company has raised gross proceeds of $378,840, in addition to the previously announced IPO gross proceeds of $8,000,000, before deducting underwriting discounts and offering expenses.
The Company issued a press release announcing the partial exercise of the over-allotment option on April 6, 2023. A copy of the press release is attached hereto as Exhibit 99.1, which is incorporated by reference herein.
This report does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| JIN MEDICAL INTERNATIONAL LTD. | ||
| Date: April 6, 2023 | By: | /s/ Erqi Wang |
| Name: | Erqi Wang | |
| Title: | Chief Executive Officer | |
2
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | Press Release on Partial Exercise of the Over-allotment Option | |
3